Cala Health is a technology company.
Cala Health has raised $127.0M across 2 funding rounds.
Cala Health has raised $127.0M in total across 2 funding rounds.
Cala Health has raised $127.0M in total across 2 funding rounds.
Cala Health's investors include Ascension Ventures, Healthy Ventures, Charlie Cheever, Jonathan Bush, Arboretum Ventures, Arcus Ventures, Beringea, AlleyCorp, Alumni Ventures, Bradley Horowitz, Fifth Wall, Kevin Love.
# Cala Health: High-Level Overview
Cala Health is a bioelectronic medicine company developing wearable neuromodulation therapies for chronic diseases, with its flagship product targeting hand tremors in essential tremor and Parkinson's disease patients[1][2]. The company transforms neurological treatment by delivering individualized peripheral nerve stimulation through a wrist-worn device rather than relying on traditional medications or invasive surgical procedures[1][2].
The company serves patients living with chronic neurological conditions who seek non-invasive, medication-free alternatives. Its core problem-solving approach addresses the significant burden of essential tremor—a condition affecting more than seven million people characterized by severe hand tremors that impair daily functioning[1][2]. Beyond tremor, Cala is expanding into neurology, cardiology, and psychiatry, positioning itself at the intersection of medical devices and digital health[1][3].
# Origin Story
Cala Health was founded in 2013 as a spinout from Stanford Biodesign, emerging from Stanford University's Neuromuscular Biomechanics laboratory[2][3]. The company was established in Silicon Valley with the explicit mission to treat movement disorders using novel non-invasive technology[3]. This academic pedigree provided early access to cutting-edge neuroscience research and clinical validation pathways.
A pivotal moment came in April 2018 when the FDA granted de novo marketing authorization for Cala Trio, the company's first product[7]. This regulatory clearance validated years of research and opened the commercial pathway. The company further accelerated development through a technology licensing collaboration with Massachusetts General Hospital and Partners Healthcare Innovation, which provided access to research on brain-cardiac function links and enhanced the company's neuromodulation platform[1].
# Core Differentiators
# Role in the Broader Tech Landscape
Cala operates at the convergence of three powerful trends: the bioelectronic medicine movement, the shift toward non-invasive neuromodulation, and the digitization of chronic disease management. As healthcare systems seek alternatives to pharmaceutical interventions—driven by side effects, dependency concerns, and cost—wearable neuromodulation represents a paradigm shift in neurological treatment.
The company's timing is strategic. Aging populations, rising prevalence of movement disorders, and FDA's increasing receptiveness to breakthrough device designations create favorable regulatory conditions[3]. Additionally, the integration of digital health infrastructure positions Cala to capture data on therapy efficacy, enabling continuous improvement and expansion into adjacent indications.
Cala influences the broader ecosystem by validating the commercial viability of bioelectronic medicine, attracting institutional investors like Kirin Holdings and venture capital firms focused on healthcare innovation[6]. The company's success demonstrates that wearable neuromodulation can achieve clinical validation, regulatory clearance, and reimbursement—a template other bioelectronic companies are now following.
# Quick Take & Future Outlook
Cala Health is positioned to become a category leader in wearable neuromodulation, with significant runway for expansion beyond tremor. The company's ability to secure Medicare coverage, FDA breakthrough designations, and partnerships with leading research institutions signals strong execution and market acceptance.
The next phase will likely involve scaling commercial adoption across the essential tremor and Parkinson's disease populations, while advancing pipeline therapies in cardiology and psychiatry. As digital health integration deepens and real-world evidence accumulates, Cala could establish itself as the reference standard for prescription electrical medicine—fundamentally reshaping how chronic neurological conditions are treated and monitored. The convergence of wearable technology, neuroscience, and healthcare economics creates a compelling long-term narrative for the company's influence and growth.
Cala Health has raised $127.0M across 2 funding rounds. Most recently, it raised $77.0M Series D in November 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2021 | $77.0M Series D | Ascension Ventures, Healthy Ventures, Charlie Cheever, Jonathan Bush | |
| May 1, 2019 | $50.0M Series C | Arboretum Ventures, Arcus Ventures, Beringea, AlleyCorp, Alumni Ventures, Ascension Ventures, Bradley Horowitz, Charlie Cheever, Fifth Wall, Healthy Ventures, Jonathan Bush, Kevin Love, Rob May |